Capital expenditure · 2012–2025
Ultragenyx Pharmaceutical capital expenditure
$6.0M−14.3% · FY2025
Ultragenyx Pharmaceutical (RARE) reported $6.0M in capital expenditure for fiscal 2025, −14.3% year on year.
| Fiscal year | Capital expenditure | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $6.0M | −14.3% | Open → |
| FY20242024-12-31 | $7.0M | −84.1% | Open → |
| FY20232023-12-31 | $44.0M | −62.1% | Open → |
| FY20222022-12-31 | $116M | +58.9% | Open → |
| FY20212021-12-31 | $73.1M | +66.5% | Open → |
| FY20202020-12-31 | $43.9M | +76.8% | Open → |
| FY20192019-12-31 | $24.8M | +509.2% | Open → |
| FY20182018-12-31 | $4.1M | +45.9% | Open → |
| FY20172017-12-31 | $2.8M | −72.6% | Open → |
| FY20162016-12-31 | $10.2M | +105.6% | Open → |
| FY20152015-12-31 | $5.0M | +130.6% | Open → |
| FY20142014-12-31 | $2.1M | +428.0% | Open → |
| FY20132013-12-31 | $407,000 | −62.7% | Open → |
| FY20122012-12-31 | $1.1M | — | Open → |
Capital expenditure — Capital expenditure is the cash the company spent during the year on property, plant and equipment — factories, stores, servers, vehicles. It appears in the investing section of the cash-flow statement as an outflow and is shown here as a positive amount. Operating cash flow minus this figure is free cash flow.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2012–2025 compound annual growth +14.0%
Capital expenditure at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Ultragenyx Pharmaceutical capital expenditure |url=https://companiesranked.com/en/company/ultragenyx-pharmaceutical/capital-expenditure |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Ultragenyx Pharmaceutical capital expenditure. CompaniesRanked. https://companiesranked.com/en/company/ultragenyx-pharmaceutical/capital-expenditureBibTeX
@misc{companiesranked-en-company-ultragenyx-pharmaceutical-capital-expenditure-2026,
author = {{CompaniesRanked}},
title = {{Ultragenyx Pharmaceutical capital expenditure}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/ultragenyx-pharmaceutical/capital-expenditure}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-057329 · February 18, 2026
{{cite web |title=Ultragenyx Pharmaceutical capital expenditure — 10-K (0001193125-26-057329) |url=https://www.sec.gov/Archives/edgar/data/1515673/000119312526057329/rare-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-18}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.